MARC Record from marc_columbia

LEADER: 03505cam a2200601 a 4500
001 6216186
005 20221122005250.0
008 060802s2006 fr a b i101 0 eng
016 7 $a101290223$2DNLM
020 $a9789283212867
020 $a928321286X
029 0 $aNLM$b101290223
029 1 $aYDXCP$b100445686
035 $a(OCoLC)ocm70866265
035 $a(OCoLC)70866265
035 $a(NNC)6216186
035 $a6216186
040 $aNLM$cNLM$dCUD$dCOU$dVAM$dBAKER$dYDXCP
042 $anlmcopyc
050 4 $aRA1231.M52$b.C6 2006
060 00 $aW1$bIA21I v.86 2006
060 10 $aQZ 202$bC652 2006
245 00 $aCobalt in hard metals and cobalt sulfate, gallium arsenide, indium phosphide, and vanadium pentoxide /$cIARC Working Group on the Evaluation of Carcinogenic Risks to Humans.
260 $aLyon, France :$bInternational Agency for Research on Cancer ;$aGeneva, Switzerland :$bDistributed by WHO Press,$c2006.
300 $axiv, 330 pages :$billustrations ;$c24 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
490 1 $aIARC monographs on the evaluation of carcinogenic risks to humans,$x1017-1606 ;$vv. 86
500 $a"This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 7-14 October 2003."
500 $aAt head of title: World Health Organization, International Agency for Research on Cancer.
504 $aIncludes bibliographical references and index.
505 2 $aMetallic cobalt particles (with or without tungsten carbide) -- Introduction to the monographs on gallium arsenide and indium phosphide. Studies of cancer in humans -- Gallium arsenide -- Indium phosphide -- Vanadium pentoxide.
650 0 $aCarcinogens.$0http://id.loc.gov/authorities/subjects/sh85020157
650 0 $aCobalt$xPhysiological effect.$0http://id.loc.gov/authorities/subjects/sh85027517
650 0 $aArsenic$xHealth aspects.
650 0 $aIndium.$0http://id.loc.gov/authorities/subjects/sh85065672
650 0 $aGallium.$0http://id.loc.gov/authorities/subjects/sh85052848
650 0 $aVanadium compounds.$0http://id.loc.gov/authorities/subjects/sh2008020195
650 0 $aTungsten.$0http://id.loc.gov/authorities/subjects/sh85138607
650 12 $aCarcinogenicity Tests.$0https://id.nlm.nih.gov/mesh/D015197
650 12 $aCarcinogens$xtoxicity.$0https://id.nlm.nih.gov/mesh/D002273Q000633
650 22 $aCobalt$xadverse effects.$0https://id.nlm.nih.gov/mesh/D003035Q000009
650 22 $aGallium$xadverse effects.$0https://id.nlm.nih.gov/mesh/D005708Q000009
650 22 $aIndium$xadverse effects.$0https://id.nlm.nih.gov/mesh/D007204Q000009
650 22 $aRisk Assessment.$0https://id.nlm.nih.gov/mesh/D018570
650 22 $aVanadium Compounds$xadverse effects.$0https://id.nlm.nih.gov/mesh/D017968Q000009
655 2 $aCongress.$0https://id.nlm.nih.gov/mesh/D016423
710 2 $aWorld Health Organization.$0http://id.loc.gov/authorities/names/n79059041
710 2 $aInternational Agency for Research on Cancer.$0http://id.loc.gov/authorities/names/n79125097
710 2 $aIARC Working Group on the Evaluation of Carcinogenic Risks to Humans$d(2003 October 7-14 :$cLyon, France)
830 0 $aIARC monographs on the evaluation of carcinogenic risks to humans ;$vv. 86.
856 42 $uhttp://monographs.iarc.fr/ENG/Monographs/vol86/volume86.pdf$zConnect to free summary and evaluation online.
852 80 $boff,hsr$hSerial$iI